Researchers at Northwestern Medicine have identified immune system markers that may help predict who responds to BCG bladder cancer therapy and who does not, according to findings published in the Journal of Clinical Investigation. The discovery could lead to more personalized treatment for bladder cancer patients, potentially sparing non-responders from ineffective therapy and its side effects.
BCG (Bacillus Calmette-Guérin) therapy is a standard immunotherapy for non-muscle invasive bladder cancer, but it fails in about 30-40% of patients. Currently, there is no reliable way to predict which patients will benefit. The Northwestern team analyzed tumor samples from patients before and after BCG treatment, identifying specific immune cell patterns and gene expression profiles associated with positive responses.
The study found that patients who responded well to BCG had higher levels of certain immune cells, including CD8+ T cells and natural killer cells, in their tumors before treatment. Additionally, gene expression analysis revealed a distinct molecular signature in responders, involving pathways related to interferon signaling and antigen presentation. Non-responders showed a more suppressive immune microenvironment.
These biomarkers could be developed into a clinical test to guide treatment decisions. For instance, patients with a favorable biomarker profile might be more likely to benefit from BCG, while those with a poor profile could be considered for alternative therapies, such as newer immunotherapies or clinical trials. The findings also open avenues for combining BCG with other agents to improve response rates.
The research aligns with broader efforts in immunotherapy refinement, including work by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which is developing novel immunotherapies for solid tumors. While the Northwestern study is still in early stages, it represents a step toward precision medicine in bladder cancer.
Bladder cancer is the sixth most common cancer in the United States, with approximately 81,000 new cases diagnosed annually. BCG therapy has been the gold standard for decades, but its variable efficacy underscores the need for predictive tools. The Northwestern team plans to validate their findings in larger clinical trials and potentially develop a commercially available test.
For more information on biomarkers and immunotherapy research, visit the Journal of Clinical Investigation.
This news is provided by TinyGems, a communications platform focusing on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @IBN.
